Age & Ovarian Reserve Influence Response to Ovarian Platelet-Rich Plasma in IVF Cycles

Objective: To evaluate the impact of patient age and ovarian reserve on response to ovarian platelet-rich plasma (PRP) in IVF cycles Design: Retrospective cohort study. Materials and Methods: Patients undergoing IVF before and after PRP were stratified by age and ovarian reserve markers, including anti-Mullerian hormone (AMH) and antral follicle count (AFC). Outcomes included oocyte yield, embryo development, and euploid embryo formation. Results: Younger patients aged <35 years (n=3) demonstrated the most robust improvement in ovarian response, with marked increases in oocyte yield and embryo development. In this group, oocyte yield increased from 21 to 38 and 26 to 43 oocytes. In select cases, there was improved embryo development, including progression from no embryos to multiple blastocysts in select cases. Patients aged 35–39 years (n=9) demonstrated moderate but more consistent improvements in ovarian response, with increased oocyte yield observed in the majority of patients. Representative increases included 11 to 21 oocytes and 12 to 19 oocytes, accompanied by improved embryo development and blastocyst formation in several cases. Patients aged ≥40 years (n=7) demonstrated more limited benefit. While some patients experienced modest increases in oocyte yield, (19 to 24 oocytes), others showed minimal change or decline. High rates of aneuploidy persisted in this group despite improved or stable oocyte yield, with most patients continuing to produce no euploid embryos or only mosaic or aneuploid embryos. Across all age groups, response to PRP was heterogeneous. 6 of 19 patients demonstrated minimal or no improvement in oocyte yield or embryo development despite similar stimulation protocols. Conclusions: Response to ovarian PRP appears to vary by patient age and underlying ovarian reserve. Although ovarian responsiveness may improve following PRP, embryo competence remains largely age-dependent. These findings suggest that patient selection is critical when considering PRP as an adjunct in IVF treatment.